Data Sheet (Cat.No.T31101)

TargetMol

CRT0273750

Chemical Properties



CAS No. : 1979939-16-6

Formula: C25H22ClF3N4O2

Molecular Weight: 502.92

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.
Targets(IC50)	LPL Receptor,PDE
In vitro	CRT0273750 is also shown to inhibit the migration of 4T1 cells with an EC50 of 0.025μM [1]. CRT0273750 shows high potency in both the biochemical (IC50 = 0.01 μM) and plasma choline release assay(IC50 = 0.014 μM)[1].
In vivo	CRT0273750 treatment shows the Cmax, AUC and t1/2 values of 3.8 μM, 3.2 μM.h and 1.4 h, respectively and shows a proportional increase[1].CRT0273750 has a moderate blood clearance, with value of 41 mL/min/kg[1].

Solubility Information

Solubility	DMSO: 200 mg/mL (397.68 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.56 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9884 mL	9.9419 mL	19.8839 mL
5 mM	0.3977 mL	1.9884 mL	3.9768 mL
10 mM	0.1988 mL	0.9942 mL	1.9884 mL
50 mM	0.0398 mL	0.1988 mL	0.3977 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Shah P, et al. Discovery of potent inhibitors of the lysophospholipase autotaxin. Bioorg Med Chem Lett. 2016 Nov 15;26(22):5403-5410.